Sinuwave | Ondine Biomedical

By: Ondine Biomedical  09-12-2011
Keywords: Product Development , Chronic Sinusitis

About Sinuwave™

Chronic Sinusitis: 

  • Every year, Chronic Sinusitis patients make 15 million visits to outpatient clinics
  • More than half of all Chronic Sinusitis outpatient visits result in prescription medication.
  • Chronic Sinusitis patients visit their primary physicians twice as often as those without the disorder, and have 5 times as many prescriptions filled
  • Chronic Sinusitis patients can spend up to 1/3 of the year on medication 

The Sinuwave™ Advantage

It is estimated that 500,000 patients currently live with chronic sinusitis that is unresponsive to both surgical intervention and medical therapy, such as antibiotics. Photodisinfection is able to destroy inflammatory molecules  and treat topical infections without generating resistance, suggesting that it will become a powerful tool in the treatment of chronic sinusitis.  

Product Development Status

This product is in the early stages of development, including in vitro testing at Ondine Research Labs.

Keywords: Chronic Sinusitis, Product Development ,

Contact Ondine Biomedical

Email - none provided

Print this page

Other products and services from Ondine Biomedical


Vitalwave | Ondine Biomedical

A charitable group known (Courthill Foundation) contracts Ondine Biomedical Corporation for the development of this potentially life saving application. Vitalwave™ is a treatment designed to decolonize the birth canal in the hopes of preventing vertical transmission of HIV and other pathogens. Vitalwave™ has undergone development to the prototype stage, and is expected to be beta tested in the near future.


MRSAid | Ondine Biomedical

It may be used adjunctively with or in replacement of topical nasal antibiotics, and offers the distinct advantages of: 1) absence of development of bacterial resistance to the killing mechanism of aPDT, 2) elimination of patient compliance issues with a multi-day treatment schedule, and 3) immediate and powerful nasal decolonization of pathogens.


Endowave (VAP) | Ondine Biomedical

Ondine believes that reducing the microbial load in ETT’s will result in reduced ventilator associated pneumonia infection rate, less reliance on antibiotics and reduced average length of hospital stay for intubated patients. Endowave™ is the first treatment using photodisinfection to eradicate bacterial biofilms on the inner surface of endotracheal tubes, thus preventing the aspiration of pathogens in a mechanically ventilated patient.


Periowave | Ondine Biomedical

Periowave™ uses the powerful photodisinfection reaction to inactivate the bacteria and toxins that are left behind after scaling and root planing.First, a small quantity of blue-coloured photosensitizer solution is topically applied to the gums at the treatment site where it attaches to microbes and toxins associated with gum disease.